Recent status and progress of chemotherapy treatment for metastatic non-small-cell lung cancer

Abstract

Abstract: In recent years, smoking,pollution and lampblack lead to the morbidity and mortality of lung cancer rapid growth. Non-small-cell lung cancer onset occult, development is rapid, and the prognosis is poor. Most of the patients with newly diagnosed is transferred (IV stage) and lost the opportunity to surgery, chemotherapy is the main treatment method, which purpose is to prolonging the survival time and the quality of life. At present clinical application of chemotherapy is mainly platinum-based and the third generation cytotoxic drugs. The best treatment strategy which based on functional genomics and proteomics in individual therapy design for every patient with lung cancer is the direction of the clinical development and the ideal mode of treatment of the 2l century. This paper reviews the recent status and progress of chemotherapy treatment for metastatic non-small-cell lung cancer.

Key words: Metastatic non-small-cell lung cancer, Chemotherapy, Individualized treatment

CLC Number:

R734

QI Quan, ZHAO Wen-ying. Recent status and progress of chemotherapy treatment for metastatic non-small-cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 573-581.

References

[1] Ahmedin J,Freddie B,Melissa M,et al. Global Cancer Statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] Visbal AL,Leighl NB,Feld R,et al.Adjuvant chemotherapy for early stage non-small cell lung cancer[J].Chest,2005,128(4):2933-2943.
[3] Non-Small Cell Lung Cancer Collaboratibe Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small-cell lung cancer[J].Cochrane Database Syst Rev,2010,(5):CD007309.
[4] Sandler AB,Nemunaitis J,Denham C,et al.Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2000,18(1):122-130.
[5] Ardizzoni A,Boni L,Tiseo M,et al.Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer:an individual patient data meta-analysis[J].J Natl Cancer Inst,2007,99(11):847-857.
[6] 刘冬英,吴海鹰,张力,等.口服长春瑞滨联合顺铂与静滴长春瑞滨联合顺铂治疗局部晚期或转移的非小细胞肺癌的II期临床研究[J].中国肿瘤临床,2010,37(14):820-824.
[7] 李婉萍.吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2009,22(6):487-488.
[8] 储天晴,林皓,沈洁.单药紫杉醇与紫杉醇联合奥沙利铂二线治疗晚期非小细胞肺癌临床疗效比较[J].中国肺癌杂志,2009,12(11):1178-1183.
[9] 赵敏,张红斌,梁健,等.紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌对比研究[J].临床肿瘤学杂志,2010,15(4):343-345.
[10] Rizvi NA,Riely GJ,Azzoli CG,et al.Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small cell lung cancer[J].J Clin Oncol,2008,26(4):639-643.
[11] 韩云辉,韩强师,刘书东.培美曲塞二钠与多西紫杉醇单药治疗晚期非小细胞肺癌的对比研究[J].中华肿瘤防治杂志,2011,18(1):57-59.
[12] Di MM,Perrone F,Chiodini P,et al.Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol,2007,25(11):1377-1382.
[13] Weiss GJ,Langer C,Rosell R,et al.Elderly patients benefit from second-line cytotoxic chemotherapy:a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2006,24(27):4405-4411.
[14] 张湘茹,朱允中,修清玉,等.伊立替康联合顺铂治疗晚期非小细胞肺癌临床报告[J].中华肿瘤杂志,2006,28(10):777-779.
[15] Yumine K,Kawahara M.Phase II study of S-1,a novel oral fluorouracil,in advanced non-small-cell lung cancer[J].Gan To Kagaku Ryoho,2006,33(1):189-192.
[16] Bhawna S,Sue A,Alison N,et al.Early Response to Platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival[J]. J Thorac Oncol,2007,2(8):735-740.
[17] Baggstrom MQ,Stinchcombe TE,Fried DB,et al.Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer:a meta-analysis[J].J Thorac Oncol,2007,2(9):845-853.
[18] Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
[19] Azim HA Jr,Elattar I,Loberiza FR Jr,et al.Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer:a systematic overview[J].Lung Cancer,2009,64(2):194-198.
[20] 王艇,马彬,杨克虎,等.第三代药物为基础的三药方案对比两药方案化学治疗晚期非小细胞肺癌的系统评价[J].中国肺癌杂志,2009,12(6):565-570.
[21] Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317-323.
[22] 刘联,王秀问,黎莉,等.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990-994.
[23] 赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408-1411.
[24] Grossi F,Aita M,Defferrari C,et al.Impact of third-generation drugs on the activity of first-line themotherapy in advanced non-small cell lung cancer:a meta-analytical approach[J].Oncologist,2009,14(5):497-510.
[25] Ceppi P,Volante M,Novello S,et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine[J].Ann Oncol,2006,17(12):1818-1825.
[26] Wei SZ,Zhan P,Shi MQ,et al.Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy:a systematic review and meta-analysis[J].Med Oncol,2011,28(1):315-321.
[27] Scagliotti GV,Parikh P,von Pawel J,et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[28] Socinski MA,Manikhas GM,Stroyakovsky DL,et al.A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplation as first-line therapy in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2010,5(6):825-861.
[29] 沈红,蔡健康,沈立,等.晚期非小细胞肺癌β-微管蛋白III表达与抗微管药敏感性Meta分析[J].循证医学,2011,11(2):102-106.
[30] Kubota K,Sakai H,Yamamoto N,et al.A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2010,5(5):702-706.
[31] Okamoto I,Fukuoka M.S-1:a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer[J].Clin Lung Cancer,2009,10(4):290-294.
[32] D`Addario G,Pintilie M,Leighl NB,et al.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:a meta-analysis of the published literature[J].J Clin Oncol,2005,23(1):2926-2936.
[33] Owonikoko TK,Ragin CC,Belani CP,et al.Lung cancer in elderly patients:an analysis of the surveillance,epitdemiology,and end results database[J].J Clin Oncol,2007,25(35):5570-5577.
[34] 李爱武,周彩存,徐建芳,等.年龄与并发症对老年晚期非小细胞肺癌患者治疗和生存期的影响[J].肿瘤,2008,28(7).596-600.
[35] Davidoff AJ,Tang M,Seal B,et al.Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2010,28(13):2191-2197.
[36] Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer.The Elderly Lung Cancer Vinorelbine Italian Study Group[J].J Natl Cancer Inst,1999,91(1):66-72.
[37] Kudoh S,Takeda K,Nakagawa K,et al.Phase III study of docetaxl compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer:results of the West Japan Thoracic Oncology Group trial(WJTOG 9904)[J].J Clin Oncol,2006,24(22):3657-3663.
[38] Smith IE,O'Brien ME,Talbot DC,et al.Duration of chemotherapy in advanced non-small-cell lung cancer:a randomized trial of three versus six courses of mitomycin,vinblastine,and cisplatin[J].J Clin Oncol,2001,19(5):1336-1343.
[39] Socinski MA,Schell MJ,Peterman A,et al.Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer[J].J Clin Oncol,2002,20(5):1335-1343.
[40] Shepherd FA,Dancey J,Ramlau R,et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J].J Clin Oncol,2000,18(10):2095-2103.
[41] Fossella FV,DeVore R,Kerr RN,et al.Randominized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.The TAX320 Non-Small Cell Lung Cancer Study Group[J].J Clin Oncol,2000,18(12):2354-2362.
[42] Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
[43] 张怡飞,虞永峰,陆舜.多西他赛单药与多西他赛联合铂类方案二线治疗晚期非小细胞肺癌的比较[J].中华医学杂志,2009,89(22):1544-1548.
[44] Segawa Y,Kiura K,Hotta K,et al.A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy:results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503[J].J Thorac Oncol,2010,5(9):1430-1434.
[45] Weiss GJ,Lange C,Rosell R,et al.Elderly patients benefit from second-line cytotoxic chemotherapy:a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2006,24(27):4405-4411.
[46] Brodowicz T,Krzakowski M,Zwitter M,et al.Cisplafin and gemcitabine first-line chemothempy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:a phase III trial[J].Lung Cancer,2006,52(2):155-163.
[47] Fidias PM,Dakhil SR,Lyss AP,et al.Phase III study of immediate compared with delayed docetaxel after front-lie therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer[J].J Clin Oncol,2009,27(4):591-598.
[48] Ciuleanu T,Brodowicz T,Zielinski C,et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study[J].Lancet,2009,374(9699):1432-1440.